NCT00670930 - Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Allergic Asthma

Interventions

DRUG

omalizumab at a dose of 0.016mg/kg/IU/mL

DRUG

Placebo

Trial Locations (16)

2333

Novartis Investigative Site, Leiden 2333 ZA

19104

Novartis Investigative Site, Philadelphia

19140

Novartis Investigative Site, Philadelphia

27710

Novartis Investigative Site, Durham

34059

Novartis Investigative Site, Montpellier

63110

Novartis Investigative Site, St Louis

80206

Novartis Investigative Site, Denver

77555-1083

Novartis Investigative Site, Galveston

T2N 4N1

Novartis Investigative Site, Calgary

H2X 2P4

Novartis Investigative Site, Montreal

G1V 4G5

Novartis Investigative Site, Québec

D-55101

Novartis Investigative Site, Mainz

SE-221 85

Novartis Investigative Site, Lund

G12 OYN

Novartis Investigative Site, Glasgow - Scotland

M20 8LR

Novartis Investigative Site, Manchester

SO16 6YD

Novartis Investigative Site, Southampton